IRIDEX (IRIX) Q2 2026 Earnings Call Transcript

IRIDEX reported Q2 revenue of $12.6M, down 7% YoY ($13.6M), driven by a $6.5M retina decline (vs. $8.0M) that was only partly offset by glaucoma growth. Glaucoma Cyclo G6 probe volume rose 35% to 17,700 units and Cyclo G6 product family revenue grew 19% to $3.9M; however, gross margin was slightly lower at 34.2% (34.5% prior year) and adjusted EBITDA was a $0.4M loss (vs. $0.021M profit). The company reaffirmed 2026 revenue guidance of $51M–$53M (excluding Middle East revenue, implying +1% to +5% pro forma growth) and operating expense guidance of $19.0M–$19.5M, while noting Q3 cash flow pressure from building safety stock ahead of a headquarters relocation. Cash increased modestly to $4.7M, and management expects low-double-digit glaucoma growth and low-single-digit retina growth in 2H 2026 despite ongoing regulatory/commercial choppiness (e.g., MDR and UK registry progress).

Analysis

IRIX is shifting from a top-line story to a cash-conversion story, and that usually compresses the multiple before it expands it. The market can forgive lumpy revenue, but not a small-cap medtech that has to spend working capital just to bridge operational transitions; that keeps dilution risk as the key equity overhang over the next 1-3 quarters. The second-order beneficiaries are contract manufacturers and distributors that absorb the inventory buffer, while the first-order loser is IRIX shareholders if the buffer is mis-sized.

The durable engine is consumable-led glaucoma utilization, not console placement. That matters because recurring probe pull-through can support a higher-quality revenue mix even if system sales wobble, but once distributor pre-buys wash out, growth could normalize faster than bulls expect. Competitively, that leaves IRIX vulnerable to share defense from better-capitalized glaucoma names like GKOS if physicians decide the switching cost is lower than management implies.

Retina is still optionality, not a base case, because the next 1-2 quarters are dominated by geography/regulatory timing rather than end-demand. The real downside catalyst is not another soft quarter; it is a financing signal, a re-acceleration in cash burn, or any evidence that inventory is being pushed into the channel faster than it is being consumed. Contrarian view: if probe utilization stays >20% and opex discipline holds, the market may be underestimating the operating leverage into 2027, but that needs repeatable proof before the stock deserves a re-rate.

Key Decisions for Investors

• No fresh long in IRIX for the next 1-2 quarters; wait for confirmation that cash remains positive after the inventory build and that revenue growth is coming from sell-through, not distributor stockpiling.
• Relative-value trade: long GKOS / short IRIX over 1-3 months to express cleaner recurring revenue quality versus IRIX's financing and execution risk. Cover the short if IRIX shows two consecutive quarters of stable cash generation without incremental working-capital drag.
• Event-driven only: buy IRIX on a post-earnings drawdown if the stock sells off on temporary channel noise but management reaffirms full-year guidance and avoids any financing language. Target a tactical 15-25% rebound into Q4 seasonality.
• Set an alert on cash falling toward $4 million or any shelf/ATM/convertible discussion; that would be the point to short or reduce exposure because dilution becomes the dominant risk.